Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation

References

• Selkoe D J. Normal and abnormal biology of the beta-amyloid precursor protein. Ann Rev Neurosci 1994; 17: 489–517
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Isolation and quantification of soluble Alzheimer's ß-peptide from biological fluids. Nature 1992; 359: 325–327
   PubMed Web of Science ®Google Scholar
• Shoji M, Golde T E, Ghiso J, Cheung T T, Estus S, Shaffer L M, Cai X D, McKay D M, Tintner R, Frangione B, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258: 126–129
   PubMed Web of Science ®Google Scholar
• Haass C, Schlossmacher M G, Hung A Y, Vigo-Pelfrey C, Mellon A, Ostaszewski B L, Lieberburg I, Koo E H, Schenk D, Teplow D B, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359: 322–325
   PubMed Web of Science ®Google Scholar
• Kirschner D A, Inouye H, Duffy L K, Sinclair A, Lind M, Selkoe D J. Synthetic peptide homologous to β protein from Alzheimer's disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 1987; 84: 6953–6957
   PubMed Web of Science ®Google Scholar
• Lorenzo A, Yankner B A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994; 91: 12243–12247
   PubMed Web of Science ®Google Scholar
• Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523–527
   PubMed Web of Science ®Google Scholar
• Haass C, De Strooper B. The presenilins in Alzheimer's disease-proteolysis holds the key. Science 1999; 286: 916–919
   PubMed Web of Science ®Google Scholar
• Schmechel D E, Saunders A M, Strittmatter W J, Crain B J, Hulette C M, Joo S H, Pericak-Vance M A, Goldgaber D, Roses A D. Increased amyloid ß-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype inlate-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 9649–9653
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–177
   PubMed Web of Science ®Google Scholar
• Zagorski M G, Yang J, Shao H, Ma K, Zeng H, Hong A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods in Enzymology 1999; 309: 189–204
   Google Scholar
• Findeis M A. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76–84
   PubMed Web of Science ®Google Scholar
• Skovronsky D M, Pijak D S, Doms R W, Lee V M. A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. Biochemistry 2000; 39: 810–817
   Google Scholar
• Bard F, Cannon C, Barbour R, Burke R L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med 2000; 6: 916–919
   PubMed Web of Science ®Google Scholar
• Goldgaber D, Schwarzman A L, Bhasin R, Gregori L, Schmechel D, Saunders A M, Roses A D, Strittmater W. Sequestration of amyloid beta protein. Ann New York Acad Sci 1993; 695: 139–143
   Google Scholar
• LeVine H, III, Scholten J D. Screening for pharmacologic inhibitors of amyloid fibril formation. Meth Enzymol 1999; 309: 467–476
   PubMed Web of Science ®Google Scholar
• Zlokovic B V, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism. Nature Med 2000; 6: 718–719
   Web of Science ®Google Scholar
• Fraser P E, Nguyen J T, McLachlan D R, Abraham C R, Kirschner D A. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61: 298–305
   PubMed Web of Science ®Google Scholar
• Schwarzman A L, Gregori L, Vitek M P, Lyubsky S, Strittmatter W J, Enghilde J J, Bhasin R, Silverman J, Weisgraber K H, Coyle P K, et al. Transthyretin sequesters amyloid ß protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994; 91: 8368–8372
   PubMed Web of Science ®Google Scholar
• Evans K C, Berger E P, Cheon-Gyu C, Weisgraber K H, Lansbury P T, Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation. Proc Natl Acad Sci USA 1995; 92: 763–767
   PubMed Web of Science ®Google Scholar
• Mazur-Kolecka B, Frackowiak J, Wisniewski H M. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res 1995; 698: 217–222
   Google Scholar
• Link C D. Expression of human β-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 1995; 92: 9368–9372
   PubMed Web of Science ®Google Scholar
• Holtzman D M, Bales K R, Wu S, Bhat P, Parsadanian M, Fagan A M, Chang L K, Sun Y, Paul S M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999; 103: R15–R21
   PubMed Web of Science ®Google Scholar
• Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone M G, Garini P, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin withamyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959–2963
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Lemieux L J, Fraser P E, Kong X, Hultin P G, Szarek W A. Arresting amyloidosis in vivio using small molecule anionic sulphonates or sulphates: implication for Alzheimer's disease. Nature Med 1995; 1: 143–148
   PubMed Web of Science ®Google Scholar
• Wood S J, MacKenzie L, Maleeff B, Hurle M R, Wetzel R. Selective inhibition of Abeta fibril formation. J Biol Chem 1996; 271: 4086–4092
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Ghilardi J R, Felix A M, Lu Y A, Vinters H V, Mantyh P W, Maggio J E. A beta deposition inhibitor screen using synthetic amyloid. Nature Biotechnol 1997; 15: 258–263
   PubMed Web of Science ®Google Scholar
• McLaurin J, Golomb R, Jurewicz A, Antel J P, Fraser P E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit a beta-induced toxicity. J Biol Chem 2000; 275: 18495–18502
   PubMed Web of Science ®Google Scholar
• Tjernberg L O, Naslund J, Lindqvist F, Johansson J, Karlstrom A R, Thyberg J, Terenius L, Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545–8548
   PubMed Web of Science ®Google Scholar
• Hughes S R, Goyal S, Sun J E, Gonzalez-DeWhitt P, Fortes M A, Riedel N, Sahasrabudhe S R. Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Proc Natl Acad Sci USA 1996; 93: 2065–2070
   PubMedGoogle Scholar
• Soto C, Sigurdsson E M, Morelli L, Kumar R A, Castano E M, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med 1998; 4: 822–826
   PubMed Web of Science ®Google Scholar
• Findeis M A, Musso G M, Arico-Muendel C C, Benjamin H W, Hundal A M, Lee J J, Chin J, Kelley M, Wakefield J, Hayward N J, et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 1999; 38: 6791–6800
   PubMed Web of Science ®Google Scholar
• Pappolla M, Bozner P, Soto C, Shao H, Robakis N K, Zagorski M, Frangione B, Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185–7188
   PubMed Web of Science ®Google Scholar
• Lomakin A, Chung D S, Benedek G B, Kirscner D A, Teplow D B. On the nucleation and growth of amyloid beta protein fibrils:detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 1996; 93: 1125–1129
   PubMed Web of Science ®Google Scholar
• Harper J D, Wong S S, Lieber C M, Lansbury P T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997; 4: 119–125
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Mantyh P W, Maggio J E. Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. Meth Enzymol Enzymol 1999; 309: 350–374
   PubMed Web of Science ®Google Scholar
• Walsh D M, Lomakin A, Benedek G B, Condron M M, Teplow D B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272: 22364–22372
   PubMed Web of Science ®Google Scholar
• Walsh D M, Hartley D M, Kusumoto Y, Fezoui Y, Condron M M, Lomakin A, Benedek G B, Selkoe D J, Teplow D B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999; 274: 25945–25952
   PubMed Web of Science ®Google Scholar
• Schwarzman A L, Goldgaber D. The nature and origin of amyloid fibrils. Ciba Foundation Symposium Wiley, Chichester 1996; 146–164
   Google Scholar
• Schwarzman A L, Tsiper M, Wente H, Wang A, Vitek M P, Vasiliev V, Goldgaber D. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid: J Protein Folding Disord 2004; 11: 1–9
   PubMed Web of Science ®Google Scholar
• Jarrett J T, Lansbury P T, Jr. Seeding “one-dimentional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie. Cell 1993; 73: 1055–1058
   PubMed Web of Science ®Google Scholar
• Vitek M P, Bhattacharya K, Glendening J M, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci 1994; 91: 4766–4770
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Jennings J M, Vinters H V, Ghilardi J R, Lee J P, Mantyh P W, Maggio J E. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 2000; 39: 6288–6295
   PubMed Web of Science ®Google Scholar
• Wisniewski H M, Frackowiak J, Mazur-Kolecka B. In vitro production of beta-amyloid in smooth muscle cells isolated from amyloid angiopathy-affected vessels. Neurosci Lett 1995; 183: 120–123
   PubMed Web of Science ®Google Scholar
• Mazur-Kolecka B, Frackowiak J, Carrol R T, Wisniewski H M. Accumulation of Alzheimer amyloid-beta peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid. J Neuropath and Exp Neurol 1997; 56: 263–272
   PubMed Web of Science ®Google Scholar
• Gallop M A, Barret R W, Dower W J, Fodor S P, Gordon E M. Application of combinatorial technologies to drug discovery. 1.Background and peptide combinatorial libraries. J Med Chem 1994; 37: 1233–1249
   PubMed Web of Science ®Google Scholar
• Egleton R, Davis T. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997; 18: 1431–1439
   PubMed Web of Science ®Google Scholar
• Prokai L. Peptide drug delivery into the central nervous system. Progress in drug research, E Jucker. Birkhauser Verlag, Basel 1998; 96–131
   Google Scholar
• Smith G P, Scott J K. Libraries of peptides and proteins displayed on filamentous phage. Methods in Enzymol 1993; 217: 228–257
   PubMed Web of Science ®Google Scholar
• Snow A D, Kinsella M G, Parks E, Sekiguchi R T, Miller J D, Kimata K, Wight T N. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Archives of Biochemistry and Biophysics 1995; 320: 84–95
   PubMed Web of Science ®Google Scholar
• Tsuzuki K, Fukatsu R, Hayashi Y, Yoshida T, Sasaki N, Takamaru Y, Yamaguchi H, Tateno M, Fuji N, Takahata N. Amyloid beta protein and transthyretin, sequestrating protein colocalize in normal human kidney. Neurosci Lett 1997; 222: 163–166
   PubMed Web of Science ®Google Scholar
• Moss M A, Varyel N H, Nichols M R, Reed D K, Rosenberry T L. Nordihydroguaiaretic acid does not disaggregate beta-amyloid (1–40) protofibrils but does inhibit growth arising from direct protofibril association. Molecular Pharmacology 2004; 66: 592–600
   Google Scholar